나노바이러사이드(NNVC)는 NYSE MKT에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.38 (+1.47%), 시가총액 $0.04B, 52주 범위 $0.85 ~ $2.03.
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediat
나노바이러사이드의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
나노바이러사이드의 현재 주가는 $1.38 (+1.47%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
나노바이러사이드의 시가총액은 약 $0.04B입니다.
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug can